Nasdaq · CIK 0001446847
IRWD IRONWOOD PHARMACEUTICALS INC
Insider trading from SEC Form 4. Last filing 25 d ago. Close $3.82 on Oct 9, 2026, +167% from the 52-week low and -29% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
IRWDOct 9, 2026 · close 3.82
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at IRONWOOD PHARMACEUTICALS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Tammi L Gaskins Chief Commercial Officer sell | $1,487 2,563 shares | -1% | 0% from low-89% from high | |
| 37Weak | Gregory S. Martini Chief Financial Officer sell | $21k 12,052 shares | -6% | - | |
| 38Weak | Minardo John Chief Legal Officer sell | $69k 38,938 shares | -9% | - | |
| 38Weak | Michael Shetzline SVP, CMO, Head-Res&Drug sell | $73k 41,269 shares | -7% | - | |
| 30Weak | Ronald Silver Principal Accounting Officer sell | $21k 12,048 shares | -4% | - | |
| 58Moderate | Thomas A MCCOURT Chief Executive Officer sell | $245k 139,064 shares | -11% | - | |
| 23Weak | Andrew Davis SVP, Chief Business Officer sell | $22k 5,360 shares | -2% | - | |
| 36Weak | Sravan Kumar Emany SVP, COO and CFO sell | $45k 11,001 shares | -3% | - |
Transactions
The last 23 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Alexander J Denner director | AGrant or award Class A Common Stock | +3,694 | $0.00 | $0 | 327,549 | 25 d ago |
| Jun 13, 2025 | Alexander J Denner director, owner | AGrant or award Class A Common Stock | +24,193 | $0.00 | $0 | 235,962 | Jun 17, 2025 |
| Jun 10, 2025 | Mark G Currie director | AGrant or award Class A Common Stock | +45,000 | $0.00 | $0 | 613,419 | Jun 12, 2025 |
| Jun 10, 2025 | Alexander J Denner director, owner | AGrant or award Class A Common Stock | +45,000 | $0.00 | $0 | 211,769 | Jun 12, 2025 |
| Jun 10, 2025 | Andrew Dreyfus director | AGrant or award Class A Common Stock | +45,000 | $0.00 | $0 | 228,313 | Jun 12, 2025 |
| Jun 10, 2025 | Jon R Duane director | AGrant or award Class A Common Stock | +45,000 | $0.00 | $0 | 190,339 | Jun 12, 2025 |
| May 16, 2025 | Tammi L Gaskins Chief Commercial Officer | SOpen-market sale Class A Common Stock | -2,563 | $0.58 | $1,487 | 242,596 | May 20, 2025 |
| Apr 2, 2025 | Alexander J Denner director, owner | AGrant or award Class A Common Stock | +10,416 | $0.00 | $0 | 166,769 | Apr 4, 2025 |
| Feb 10, 2025 | Michael Shetzline SVP, CMO, Head-Res&Drug | AGrant or award Class A Common Stock | +133,333 | $0.00 | $0 | 595,276 | Feb 12, 2025 |
| Feb 10, 2025 | Thomas A MCCOURT Chief Executive Officer | SOpen-market sale Class A Common Stock | -139,064 | $1.76 | $245k | 1,160,634 | Feb 12, 2025 |
| Feb 10, 2025 | Ronald Silver Principal Accounting Officer | SOpen-market sale Class A Common Stock | -12,048 | $1.76 | $21k | 279,655 | Feb 12, 2025 |
| Feb 10, 2025 | Minardo John Chief Legal Officer | AGrant or award Class A Common Stock | +122,222 | $0.00 | $0 | 447,070 | Feb 12, 2025 |
| Feb 10, 2025 | Gregory S. Martini Chief Financial Officer | SOpen-market sale Class A Common Stock | -12,052 | $1.76 | $21k | 183,810 | Feb 12, 2025 |
| Feb 10, 2025 | Minardo John Chief Legal Officer | SOpen-market sale Class A Common Stock | -38,938 | $1.76 | $69k | 408,132 | Feb 12, 2025 |
| Feb 10, 2025 | Michael Shetzline SVP, CMO, Head-Res&Drug | SOpen-market sale Class A Common Stock | -41,269 | $1.76 | $73k | 554,007 | Feb 12, 2025 |
| Jan 27, 2025 | Gregory S. Martini Chief Financial Officer | AGrant or award Class A Common Stock | +111,111 | $0.00 | $0 | 195,862 | Jan 29, 2025 |
| Jan 27, 2025 | Ronald Silver Principal Accounting Officer | AGrant or award Class A Common Stock | +133,333 | $0.00 | $0 | 291,703 | Jan 29, 2025 |
| Jan 17, 2025 | Thomas A MCCOURT Chief Executive Officer | AGrant or award Class A Common Stock | +147,354 | $0.00 | $0 | 1,299,698 | Jan 22, 2025 |
| Jan 17, 2025 | Minardo John Chief Legal Officer | AGrant or award Class A Common Stock | +40,187 | $0.00 | $0 | 324,848 | Jan 22, 2025 |
| Jan 17, 2025 | Michael Shetzline SVP, CMO, Head-Res&Drug | AGrant or award Class A Common Stock | +48,224 | $0.00 | $0 | 461,943 | Jan 22, 2025 |
| Dec 16, 2024 | Alexander J Denner director, owner | AGrant or award Class A Common Stock | +4,249 | $0.00 | $0 | 156,353 | Dec 18, 2024 |
| Nov 18, 2024 | Andrew Davis SVP, Chief Business Officer | SOpen-market sale Class A Common Stock | -5,360 | $4.08 | $22k | 284,685 | Nov 20, 2024 |
| Nov 18, 2024 | Sravan Kumar Emany SVP, COO and CFO | SOpen-market sale Class A Common Stock | -11,001 | $4.08 | $45k | 309,572 | Nov 20, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Mark G Curriedirector
- Alexander J Dennerdirector, owner
- Andrew DavisSVP, Chief Business Officer
- Andrew Dreyfusdirector
- Jon R Duanedirector
- Sravan Kumar EmanySVP, COO and CFO
- Tammi L GaskinsChief Commercial Officer
- Minardo JohnChief Legal Officer
- Thomas A MCCOURTChief Executive Officer
- Gregory S. MartiniChief Financial Officer
- Michael ShetzlineSVP, CMO, Head-Res&Drug
- Ronald SilverPrincipal Accounting Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.